Literature DB >> 31200236

Tetrazole hybrids with potential anticancer activity.

Jingyu Zhang1, Su Wang2, Yanyan Ba2, Zhi Xu3.   

Abstract

Cancer is one of the main causes of death throughout the world. The anticancer agents are indispensable for the treatment of various cancers, but most of them currently on the market are not specific, resulting in series of side effects of chemotherapy. Moreover, the emergency of drug-resistance towards cancers has already increased up to alarming level in the recent decades. Therefore, it's imperative to develop novel anticancer candidates with excellent activity against both drug-susceptible and drug-resistant cancers, and low toxicity as well. Tetrazole is the bioisoster of carboxylic acid, and its derivatives demonstrated promising anticancer activity. Hybridization of tetrazole with other anticancer pharmacophores may provide novel candidates with anticancer potency. The present review described the anticancer activity of tetrazole hybrids, and the structure-activity relationship (SAR) is also discussed to provide an insight for rational designs of tetrazole anticancer candidates with higher efficiency.
Copyright © 2019 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Anticancer activity; Hybrid compounds; Structure-activity relationship; Tetrazole

Mesh:

Substances:

Year:  2019        PMID: 31200236     DOI: 10.1016/j.ejmech.2019.05.071

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  5 in total

1.  Functionalization of Tetrazoles Bearing the Electrochemically Cleavable 1N-(6-Methylpyridyl-2-methyl) Protecting Group.

Authors:  Konstantinos Grammatoglou; Madara Da Rziņa; Aigars Jirgensons
Journal:  ACS Omega       Date:  2022-05-16

2.  A One-Pot Six-Component Reaction for the Synthesis of 1,5-Disubstituted Tetrazol-1,2,3-Triazole Hybrids and Their Cytotoxic Activity against the MCF-7 Cell Line.

Authors:  Cesia M Aguilar-Morales; Jorge Gustavo Araujo-Huitrado; Yamilé López-Hernández; Claudia Contreras-Celedón; Alejandro Islas-Jácome; Angelica Judith Granados-López; Cesar R Solorio-Alvarado; Jesús Adrián López; Luis Chacón-García; Carlos J Cortés-García
Journal:  Molecules       Date:  2021-10-10       Impact factor: 4.411

3.  Novel 1,2,3-Triazole-Coumarin Hybrid Glycosides and Their Tetrazolyl Analogues: Design, Anticancer Evaluation and Molecular Docking Targeting EGFR, VEGFR-2 and CDK-2.

Authors:  Wael A El-Sayed; Fahad M Alminderej; Marwa M Mounier; Eman S Nossier; Sayed M Saleh; Asmaa F Kassem
Journal:  Molecules       Date:  2022-03-22       Impact factor: 4.411

4.  Design, Synthesis, and Molecular Docking Studies of Some New Quinoxaline Derivatives as EGFR Targeting Agents.

Authors:  Vinitha Badithapuram; Satheesh Kumar Nukala; Narasimha Swamy Thirukovela; Gouthami Dasari; Ravinder Manchal; Srinivas Bandari
Journal:  Russ J Bioorg Chem       Date:  2022-06-21       Impact factor: 1.254

5.  Synthesis and Rational Design of New Appended 1,2,3-Triazole-uracil Ensembles as Promising Anti-Tumor Agents via In Silico VEGFR-2 Transferase Inhibition.

Authors:  Nadipolla Naresh Reddy; Sung-Jen Hung; Merugu Kumara Swamy; Ananthula Sanjeev; Vankadari Srinivasa Rao; Rondla Rohini; Atcha Krishnam Raju; Kuthati Bhaskar; Anren Hu; Puchakayala Muralidhar Reddy
Journal:  Molecules       Date:  2021-03-30       Impact factor: 4.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.